Products for Research Use Only
RegisterLogin

Glecirasib

CAT: 0804-HY-143589-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-143589-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Glecirasib (Compound 1-2; JAB-21822) is an orally active and potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. Glecirasib has the potential for the research of KRAS G12C-mediated cancer[1][2][3][4].
CAS Number
2657613-87-9
Product Name Alternative
JAB-21822; KRAS G12C inhibitor 36
UNSPSC
12352005
Target
Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/glecirasib.html
Purity
99.20
Solubility
DMSO : 10 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
N#CC1=C(N2CCN(CC2)C(C=C)=O)C3=C(N=C(C4=C(N)C(F)=C(F)C(F)=C4F)C(Cl)=C3)N(C5=C(C)C=CN=C5C(C)C)C1=O
Molecular Formula
C31H26ClF4N7O2
Molecular Weight
640.03
References & Citations
[1]Amin LI, et al. Kras mutant protein inhibitors. Patent WO2021121367A1.|[2]Li J, Shen L, Gu Y, et al. Preliminary activity and safety results of KRAS G12C inhibitor glecirasib (JAB-21822) in patients with pancreatic cancer and other solid tumors[J]. 2024.|[3]Ma C, et al. Discovery of JAB-3312, a Potent SHP2 Allosteric Inhibitor for Cancer Treatment. J Med Chem. 2024 Aug 22;67 (16) :13534-13549. |[4]Fuerst M L. Glecirasib Induces Promising Efficacy in Patients With Advanced Lung Cancer[J]. 2024.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3

Alternative Products

CatalogName
T78651-01Glecirasib
A24226-1Glecirasib (JAB-21822) 1mg
A24226-10Glecirasib (JAB-21822) 10mg
A24226-5Glecirasib (JAB-21822) 5mg
A24226-50Glecirasib (JAB-21822) 50mg

Popular Products